Emergence of Candida auris in intensive care units in Algeria.
Candida auris
Algeria
ICU
clades (I-IV)
emergence
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
03
05
2022
received:
12
04
2022
accepted:
09
05
2022
pubmed:
14
5
2022
medline:
22
6
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Currently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly. Here, we report for the first time in Algeria seven cases of C. auris infection or colonisation. The strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital. Appropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly.
OBJECTIVE
OBJECTIVE
Here, we report for the first time in Algeria seven cases of C. auris infection or colonisation.
METHODS AND RESULTS
RESULTS
The strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital.
CONCLUSIONS
CONCLUSIONS
Appropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.
Identifiants
pubmed: 35546294
doi: 10.1111/myc.13470
pmc: PMC9328195
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
753-759Subventions
Organisme : Agence Nationale de la Recherche
Informations de copyright
© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
J Hosp Infect. 2017 Dec;97(4):363-370
pubmed: 28939316
Clin Infect Dis. 2017 Jan 15;64(2):134-140
pubmed: 27988485
Am J Transplant. 2017 Jan;17(1):296-299
pubmed: 28029734
Mycoses. 2022 Feb;65(2):134-139
pubmed: 34780087
Lancet Infect Dis. 2018 Dec;18(12):1377-1384
pubmed: 30293877
Antimicrob Resist Infect Control. 2020 Apr 7;9(1):50
pubmed: 32264966
PLoS Pathog. 2017 May 18;13(5):e1006290
pubmed: 28542486
Microbiol Immunol. 2009 Jan;53(1):41-4
pubmed: 19161556
Int J Infect Dis. 2019 Aug;85:182-187
pubmed: 31185293
J Clin Microbiol. 2015 Jun;53(6):1823-30
pubmed: 25809970
J Clin Microbiol. 2017 Oct;55(10):2996-3005
pubmed: 28747370
J Mycol Med. 2021 Sep;31(3):101139
pubmed: 33965885
Med Mycol. 2020 Jan 1;58(1):124-127
pubmed: 30874806
Emerg Infect Dis. 2019 Jan;25(1):192-194
pubmed: 30561310
Med Mycol. 2013 Oct;51(7):713-20
pubmed: 23611419
PLoS Pathog. 2020 Oct 22;16(10):e1008921
pubmed: 33091071
Eur J Clin Microbiol Infect Dis. 2021 Jul;40(7):1547-1551
pubmed: 33515096
Microbiologyopen. 2018 Aug;7(4):e00578
pubmed: 29345117
J Mycol Med. 2018 Sep;28(3):568-573
pubmed: 30030072
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28584152
Emerg Infect Dis. 2019 Sep;25(9):1763-1765
pubmed: 31223105
J Fungi (Basel). 2021 May 29;7(6):
pubmed: 34072592
Nat Med. 2021 Aug;27(8):1401-1409
pubmed: 34155414
PLoS Pathog. 2019 Apr 8;15(4):e1007638
pubmed: 30958866
J Antimicrob Chemother. 2017 Jun 1;72(6):1794-1801
pubmed: 28333181
Mycoses. 2022 Jul;65(7):753-759
pubmed: 35546294
mBio. 2020 Jan 7;11(1):
pubmed: 31911492
Am J Infect Control. 2021 Jun;49(6):804-807
pubmed: 33485922
Emerg Infect Dis. 2018 Nov;24(11):2036-2040
pubmed: 30334713
MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):514-515
pubmed: 28520710
Emerg Microbes Infect. 2021 Dec;10(1):1300-1308
pubmed: 34176429
Med Mycol. 2016 Mar;54(3):256-65
pubmed: 26613703
J Fungi (Basel). 2020 Nov 21;6(4):
pubmed: 33233388
BMC Infect Dis. 2020 Nov 11;20(1):827
pubmed: 33176724
Front Microbiol. 2019 Aug 20;10:1918
pubmed: 31481947
Clin Microbiol Rev. 2017 Nov 15;31(1):
pubmed: 29142078
J Glob Antimicrob Resist. 2020 Jun;21:181-185
pubmed: 31655136
mBio. 2020 Apr 28;11(2):
pubmed: 32345637
mSphere. 2019 Jul 31;4(4):
pubmed: 31366705
Mycopathologia. 2019 Jun;184(3):353-365
pubmed: 31209693
Expert Rev Anti Infect Ther. 2020 Jun;18(6):551-562
pubmed: 32237924
J Fungi (Basel). 2020 Sep 22;6(3):
pubmed: 32971857